Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide

McTyre, Emory, MD, MS*; Lucas, John T., MD, MS*; Helis, Corbin, MD*; Farris, Michael, MD*; Soike, Michael, MD*; Mott, Ryan, MD†,‡; Laxton, Adrian W., MD‡,§; Tatter, Stephen B., MD, PhD‡,§; Lesser, Glenn J., MD‡,∥; Strowd, Roy E., MD‡,∥,¶; Lo, Hui-Wen, PhD‡,#; Debinski, Waldemar, MD, PhD‡,¶; Chan, Michael D., MD*,‡

American Journal of Clinical Oncology: August 2018 - Volume 41 - Issue 8 - p 813–819
doi: 10.1097/COC.0000000000000380
Original Articles: Central Nervous System

Objectives: Postoperative management of anaplastic glioma remains without a clear standard of care—in this study we report outcomes for patients treated with radiotherapy (RT) with and without temozolomide (TMZ).

Materials and Methods: We identified 71 consecutive patients with World Health Organization grade III glioma treated with either RT alone or with concurrent TMZ (RT+TMZ), between 2000 and 2013. Tumor histology was anaplastic astrocytoma in 42 patients, anaplastic oligodendroglioma in 25 patients, and anaplastic oligoastrocytoma in 4 patients. In total, 26 patients received RT and 45 received RT+TMZ. Adjuvant TMZ was administered to 12/26 (46.1%) patients who received RT and 42/45 (93.3%) patients who received RT+TMZ. Time-to-event endpoints included progression-free survival (PFS) and overall survival (OS).

Results: Kaplan-Meier estimates revealed that patients receiving RT+TMZ followed by adjuvant TMZ had improved PFS (P=0.04) and OS (P=0.02) as compared with those receiving RT followed by adjuvant TMZ. Cox proportional hazards multivariate analysis revealed improved PFS and OS with RT+TMZ for all patients (PFS: hazard ratio [HR]=0.42, P=0.02; OS: HR=0.41, P=0.03) and for anaplastic astrocytoma patients (PFS: HR=0.35, P=0.03; OS: HR=0.26, P=0.01), regardless of whether patients received further adjuvant TMZ.

Conclusions: These findings support the use of RT+TMZ in the postoperative management of grade III glioma, and suggest that there is a benefit to concurrent RT+TMZ that is independent of adjuvant monthly TMZ. Further investigation is warranted, both to prospectively validate the benefit of RT+TMZ, as well as to determine if an additional benefit truly exists for adjuvant TMZ following concurrent RT+TMZ.

Departments of *Radiation Oncology



Internal Medicine, Section on Hematology and Oncology


#Cancer Biology

Brain Tumor Center of Excellence, Wake Forest School of Medicine, Winston-Salem, NC

The authors declare no conflicts of interest.

Reprints: Emory McTyre, MD, MS, Department of Radiation Oncology, Wake Forest University Baptist Medical Center, 1st Floor, Comprehensive Cancer Center, Winston-Salem, NC 27157. E-mail:

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.